Important: New Login Process
We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.
- If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
- If you log in with a username and password, you will be prompted to set a new password before accessing your account.
Go to the Login Page to get started.
We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a company name.
Bioxcel Therapeutics Inc.
Headquarters: New Haven, CT, United States of America
Website: http://www.bioxceltherapeut...
Year Founded: 2017
Status: Public
Industry Sector: HealthTechnology
CEO: Vimal D. Mehta, PhD
Number Of Employees: 74
Enterprise Value: $122,093,550
PE Ratio: -0.07
Exchange/Ticker 1: NASDAQ:BTAI
Exchange/Ticker 2: N/A
Latest Market Cap: $7,600,300
BioCentury | Feb 17, 2024
Finance
Public equity report: Five follow-ons total $875M+, PIPEs keep flowing
Plus: LianBio begins winding down, promises dividend; BioXcel pulls offering
BioCentury | Dec 13, 2023
Management Tracks
Magargee named CEO of Genentech
Plus: Garay steps down Moderna’s head of commercial and updates from MaxCyte, Aiolos, Corsair, BioXcel and more
BioCentury | Oct 25, 2023
Deals
Oct. 24 Quick Takes: BMS buying back Asia rights to mavacamten from LianBio
Plus: Rampart raises $85M series A for DNA-based therapies and updates from Servier, Novartis, Cargo and more
BioCentury | Aug 15, 2023
Deals
Aug. 14 Quick Takes: Second bidder drove up price in Biogen-Reata deal
Plus: Approval for Pfizer’s MM bispecific and updates from Harmony-Zynerba, One Bio-Hengrui, Taysha, Arcturus, BioXcel
BioCentury | Jun 29, 2023
Product Development
June 29 Quick Takes: Disclosure of impropriety jeopardizes integrity of BioXcel’s trial
Plus: Laekna completes $101M Hong Kong IPO, FDA again rebuffs Alvotech’s Humira biosimilar and updates from Vesalius, Alkermes and Vertex Ventures
BioCentury | May 26, 2023
Finance
May 25 Quick Takes: VarmX is latest biotech to extend series B
Plus: Apellis/Sobi candidate misses in ALS and updates from Annexon, Pfizer and more
BioCentury | Apr 5, 2023
Data Byte
The market cap performance of the 2018 class of U.S. IPOs
At year-end, twice as many of the companies had lost value since their IPOs than gained value
BioCentury | Feb 14, 2023
Deals
Feb. 14 Quick Takes: Vir to advance next-gen COVID assets without GSK
Plus: Cullinan licenses HBM bispecific and updates from Fusion, BioXcel, Incyte and more
BioCentury | Feb 1, 2023
Management Tracks
Okuzawa made president, COO of Daiichi
Plus: new commercial head at Karuna, and updates from Casma, CBER, Optinose, Rally Bio and more
BioCentury | Apr 20, 2022
Deals
April 19 Quick Takes: Flagship-founded Tessera raises $300M from broad syndicate
Plus: Schizophrenia setback for Teva, MedinCell and updates from BioXcel, Moderna, J&J, Unlearn, Amgen and more
Items per page:
1 - 10 of 24